This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herman, T. S. Articles by Lee, M.-H. Search for Related Content PubMed PubMed Citation Articles by Herman, T. S. Articles by Lee, M.-H.

Effect of Hyperthermia on cis-Diamminedichloroplatinum(II) (Rhodamine 123)₂[tetrachloroplatinum(II)] in a Human Squamous Cell Carcinoma Line and a cis-Diamminedichloroplatinum(II)-resistant Subline¹

Dana-Farber Cancer Institute [T. S. H., B. A. T., K. N. S. C., M. E. K., J. B. L., M-H. L.] and Joint Center for Radiation Therapy [T. S. H.], Boston, Massachusetts 02115

The effect of concomitant hyperthermia on the cytotoxicities of cis-diamminedichloroplatinum(II) (CDDP), a newly synthesized drug, Pt(Rh-123)₂, and its chemical components, K₂PtCl₄ and rhodamine 123, was examined in vitro in a squamous cell tumor line of human origin (SCC-25) and in a CDDP-resistant subline (SCC-25/CP). No difference in the cytotoxicity of hyperthermia alone was observed between these cell lines. The dose-dependent cytotoxicities of 1-h exposures to CDDP and Pt(Rh-123)₂ were markedly increased at 42°C and 43°C in comparison to 37°C, and this effect was of the same magnitude in both cell lines (enhancements of approximately 1.5 logs at 42°C and 2.5 logs at 43°C for CDDP and 1.5 logs at 42°C and >3 logs at 43°C for Pt(Rh-123)₂). The use of hyperthermia with CDDP, however, did not lower survivals in the SCC-25/CP cells even to the levels seen in the parent line at 37°C. The cytotoxicities of K₂PtCl₄ and rhodamine 123 were essentially the same in the CDDP-sensitive and -resistant cells at all temperatures tested. The magnitude of the temperature effect was significantly greater for Pt(Rh-123)₂ than for its chemical components. No significant effect on CDDP or Pt(Rh-123)₂ accumulation was observed at 42, 43, 44 or 45°C in either cell line. DNA lesions, measured by alkaline elution, were significantly enhanced for CDDP in the SCC-25 cells at 42°C. These results suggest that treatment with hyperthermia and either CDDP or Pt(Rh-123)₂ should result in supraadditive anti-tumor effects, although the efficacy of CDDP plus hyperthermia will be significantly less once resistance to CDDP has developed. Since resistance to CDDP does not imply cross-resistance to Pt(Rh-123)₂, and since the effect of hyperthermia is somewhat greater for Pt(Rh-123)₂ than for CDDP at 43°C, Pt(Rh-123)₂ may be more selectively toxic to tumor cells when used with local hyperthermia versus normal cells outside the treated area, especially if resistance to CDDP has already developed.

¹ This work was supported by National Cancer Institute Grant R01-36508 (B. A. T.) and grants from the Deaconness Hospital and the Fuller Fund (T. S. H.).

² To whom requests for reprints should be addressed.

Received 12/10/87. Revised 4/19/88. Revised 5/27/88. Accepted 6/17/88.

This article has been cited by other articles:

				C. J Gordon The therapeutic potential of regulated hypothermia Emerg. Med. J., March 1, 2001; 18(2): 81 - 89. [Abstract] [Full Text]

				B. Teicher, T. Herman, S. Holden, Y. Wang, M. Pfeffer, J. Crawford, and E Frei 3rd Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo Science, March 23, 1990; 247(4949): 1457 - 1461. [Abstract] [PDF]